派林生物
(000403)
| 流通市值：92.94亿 | | | 总市值：93.90亿 |
| 流通股本：9.41亿 | | | 总股本：9.50亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 829,843,121.92 | 342,919,344.14 | 2,632,607,334.51 | 1,618,146,526.33 |
| 营业收入 | 829,843,121.92 | 342,919,344.14 | 2,632,607,334.51 | 1,618,146,526.33 |
| 二、营业总成本 | 733,971,078.38 | 316,465,168.44 | 2,019,433,608.71 | 1,204,150,334.5 |
| 营业成本 | 556,684,902.96 | 223,499,938.44 | 1,539,167,751.82 | 868,646,327.51 |
| 税金及附加 | 12,091,440.55 | 6,170,862.56 | 22,255,740.07 | 14,640,057.04 |
| 销售费用 | 76,668,211.74 | 45,677,878.4 | 243,229,998.07 | 179,067,929.21 |
| 管理费用 | 84,034,243.46 | 38,316,203.85 | 194,937,098.61 | 138,553,932.73 |
| 研发费用 | 16,423,719.25 | 10,336,482 | 55,919,841.23 | 30,911,706.33 |
| 财务费用 | -11,931,439.58 | -7,536,196.81 | -36,076,821.09 | -27,669,618.32 |
| 其中:利息费用 | 11,124,834.47 | 4,920,219.49 | 18,191,761.04 | 12,798,979.15 |
| 其中:利息收入 | 23,281,971.32 | 12,497,823.67 | 54,567,975.78 | 40,735,386.21 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -180,180.4 | -975,780.83 | 4,296,114.07 | -5,803,891.09 |
| 加:投资收益 | 3,538,606.1 | 3,024,189.41 | 8,953,532.37 | 16,100,625.79 |
| 资产处置收益 | -135,615.12 | -18,282.45 | 756,002.27 | 764,814.04 |
| 资产减值损失(新) | -365,386.04 | - | -100,052,963.37 | -1,224,723.08 |
| 信用减值损失(新) | 916,875.68 | 1,933,662.83 | -9,360,553.88 | 357,346.67 |
| 其他收益 | 3,651,248.2 | 1,361,545.27 | 9,444,518.85 | 7,272,323.47 |
| 四、营业利润 | 103,297,591.96 | 31,779,509.93 | 527,210,376.11 | 431,462,687.63 |
| 加:营业外收入 | 2,124.43 | 4,490.12 | 2,219,620.81 | 24,028.32 |
| 减:营业外支出 | 4,420,152.74 | 2,707,816.71 | 29,128,593.56 | 24,549,716.5 |
| 五、利润总额 | 98,879,563.65 | 29,076,183.34 | 500,301,403.36 | 406,936,999.45 |
| 减:所得税费用 | 13,905,973.06 | 6,344,635.94 | 80,765,451.46 | 49,439,659.67 |
| 六、净利润 | 84,973,590.59 | 22,731,547.4 | 419,535,951.9 | 357,497,339.78 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 84,973,590.59 | 22,731,547.4 | 419,535,951.9 | 357,497,339.78 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 84,300,956.84 | 22,968,833.2 | 419,266,377.5 | 357,181,135.91 |
| 少数股东损益 | 672,633.75 | -237,285.8 | 269,574.4 | 316,203.87 |
| 扣除非经常损益后的净利润 | 64,809,700.19 | 12,978,384.56 | 384,746,741.22 | 323,356,534.14 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.02 | 0.44 | 0.38 |
| (二)稀释每股收益 | 0.09 | 0.02 | 0.44 | 0.38 |
| 八、其他综合收益 | -19,747.23 | -9,967.72 | -13,438.93 | -6,950.72 |
| 归属于母公司股东的其他综合收益 | -19,747.23 | -9,967.72 | -13,438.93 | -6,950.72 |
| 九、综合收益总额 | 84,953,843.36 | 22,721,579.68 | 419,522,512.97 | 357,490,389.06 |
| 归属于母公司股东的综合收益总额 | 84,281,209.61 | 22,958,865.48 | 419,252,938.57 | 357,174,185.19 |
| 归属于少数股东的综合收益总额 | 672,633.75 | -237,285.8 | 269,574.4 | 316,203.87 |
| 公告日期 | 2026-08-24 | 2026-04-29 | 2026-04-29 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |